600572 康恩贝
已收盘 01-12 15:00:00
资讯
新帖
简况
每周股票复盘：康恩贝（600572）Q4行权新增963.857万股
证券之星 · 01-11 04:09
每周股票复盘：康恩贝（600572）Q4行权新增963.857万股
康恩贝（600572）披露2025年第四季度股票期权激励计划自主行权结果暨股份变动公告，1月5日股价上涨0.67%
证券之星 · 01-05
康恩贝（600572）披露2025年第四季度股票期权激励计划自主行权结果暨股份变动公告，1月5日股价上涨0.67%
每周股票复盘：康恩贝（600572）子公司获药品注册证书
证券之星 · 01-02
每周股票复盘：康恩贝（600572）子公司获药品注册证书
康恩贝最新公告：选举应徐颉任董事长
证券之星 · 2025-12-30
康恩贝最新公告：选举应徐颉任董事长
每周股票复盘：康恩贝（600572）股东会增补两名董事
证券之星 · 2025-12-28
每周股票复盘：康恩贝（600572）股东会增补两名董事
A股公告精选 | 康恩贝(600572.SH)拟转让2%公司股份
智通财经网 · 2025-12-22
A股公告精选 | 康恩贝(600572.SH)拟转让2%公司股份
康恩贝公告股东计划于1月16日至4月15日之间减持最多2%的股份
美股速递 · 2025-12-22
康恩贝公告股东计划于1月16日至4月15日之间减持最多2%的股份
康恩贝(600572.SH)控股股东拟增持1.999%公司股份
智通财经 · 2025-12-22
康恩贝(600572.SH)控股股东拟增持1.999%公司股份
康恩贝董事长“闪离”背后：频繁人事震荡与增长乏力下的治理隐忧
新浪证券 · 2025-12-12
康恩贝董事长“闪离”背后：频繁人事震荡与增长乏力下的治理隐忧
康恩贝（600572）披露关于减少注册资本通知债权人的公告，11月28日股价下跌0.65%
证券之星 · 2025-11-28
康恩贝（600572）披露关于减少注册资本通知债权人的公告，11月28日股价下跌0.65%
康恩贝（600572）披露2022年股票期权激励计划首次授予股票期权第二个行权期自主行权实施公告，11月24日股价上涨0.44%
证券之星 · 2025-11-24
康恩贝（600572）披露2022年股票期权激励计划首次授予股票期权第二个行权期自主行权实施公告，11月24日股价上涨0.44%
浙金信托接手大连万达商管旗下两家公司
澎湃新闻 · 2025-11-24
浙金信托接手大连万达商管旗下两家公司
每周股票复盘：康恩贝（600572）集团减持1%股份至12.792%
证券之星 · 2025-11-16
每周股票复盘：康恩贝（600572）集团减持1%股份至12.792%
11月11日康恩贝发布公告，股东减持470.26万股
证券之星 · 2025-11-11
11月11日康恩贝发布公告，股东减持470.26万股
每周股票复盘：康恩贝（600572）股东减持2376.16万股
证券之星 · 2025-11-09
每周股票复盘：康恩贝（600572）股东减持2376.16万股
11月6日康恩贝发布公告，股东减持2376.16万股
证券之星 · 2025-11-06
11月6日康恩贝发布公告，股东减持2376.16万股
每周股票复盘：康恩贝（600572）Q3净利增69.11%，股东户数降3.48%
证券之星 · 2025-11-02
每周股票复盘：康恩贝（600572）Q3净利增69.11%，股东户数降3.48%
康恩贝(600572)9月30日股东户数8.67万户，较上期减少3.48%
证券之星 · 2025-10-28
康恩贝(600572)9月30日股东户数8.67万户，较上期减少3.48%
康恩贝最新公告：第三季度净利润为2.3亿元同比增长69.11%
证券之星 · 2025-10-28
康恩贝最新公告：第三季度净利润为2.3亿元同比增长69.11%
康恩贝最新公告：腺苷钴胺胶囊拟中标第十一批全国药品集中采购
证券之星 · 2025-10-28
康恩贝最新公告：腺苷钴胺胶囊拟中标第十一批全国药品集中采购
加载更多
公司概况
公司名称：
浙江康恩贝制药股份有限公司
所属行业：
医药制造业
上市日期：
2004-04-12
主营业务：
浙江康恩贝制药股份有限公司的主营业务是药品、中药饮片及大健康产品的研发、制造及销售。公司的主要产品是中成药、中药材与中药饮片、中药保健品及中药提取物、中药OTC及中药处方药业务。
发行价格：
8.25
{"stockData":{"symbol":"600572","market":"SH","secType":"STK","nameCN":"康恩贝","latestPrice":4.53,"timestamp":1768201201000,"preClose":4.52,"halted":0,"volume":33395064,"delay":0,"changeRate":0.0022,"floatShares":2528000000,"shares":2535000000,"eps":0.2715,"marketStatus":"已收盘","change":0.01,"latestTime":"01-12 15:00:00","open":4.5,"high":4.53,"low":4.49,"amount":151000000,"amplitude":0.0088,"askPrice":4.53,"askSize":695,"bidPrice":4.52,"bidSize":6254,"shortable":0,"etf":0,"ttmEps":0.2715,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768267800000},"marketStatusCode":5,"adr":0,"adjPreClose":4.52,"symbolType":"stock","openAndCloseTimeList":[[1768181400000,1768188600000],[1768194000000,1768201200000]],"highLimit":4.97,"lowLimit":4.07,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2534568941,"isCdr":false,"pbRate":1.63,"roa":"--","peRate":16.685083,"roe":"8.05%","epsLYR":0.25,"committee":0.11047,"marketValue":11482000000,"turnoverRate":0.0132,"status":0,"floatMarketCap":11451000000},"requestUrl":"/m/hq/s/600572","defaultTab":"news","newsList":[{"id":"2602364925","title":"每周股票复盘：康恩贝（600572）Q4行权新增963.857万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2602364925","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602364925?lang=zh_cn&edition=full","pubTime":"2026-01-11 04:09","pubTimestamp":1768075749,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，康恩贝报收于4.52元，较上周的4.46元上涨1.35%。本周，康恩贝1月7日盘中最高价报4.52元。康恩贝当前最新总市值114.56亿元，在中药板块市值排名20/67，在两市A股市值排名1793/5182。公司公告汇总浙江康恩贝制药股份有限公司2025年第四季度，2022年股票期权激励计划激励对象行权且完成股份过户登记的股票数量合计为963.8570万股，募集资金3,498.80万元，全部用于补充流动资金。本次行权新增股份为无限售条件流通股，股本总额增加至2,534,568,941股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001370.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600572","BK0239","BK0060","BK0188","BK0012","BK0097","BK0028"],"gpt_icon":0},{"id":"2601887005","title":"康恩贝（600572）披露2025年第四季度股票期权激励计划自主行权结果暨股份变动公告，1月5日股价上涨0.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601887005","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601887005?lang=zh_cn&edition=full","pubTime":"2026-01-05 22:39","pubTimestamp":1767623959,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，康恩贝报收于4.49元，较前一交易日上涨0.67%，最新总市值为113.8亿元。近日，康恩贝发布《关于2025年第四季度股票期权激励计划自主行权结果暨股份变动公告》。公告显示，2025年第四季度，公司2022年股票期权激励计划的激励对象行权且完成股份过户登记的股票数量合计为963.8570万股，募集资金3,498.80万元，全部用于补充流动资金。本次行权新增股份为无限售条件流通股，股本总额增加至2,534,568,941股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500040446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600572","BK0239","BK0060","BK0188","BK0012","BK0097","BK0028"],"gpt_icon":0},{"id":"2600770035","title":"每周股票复盘：康恩贝（600572）子公司获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2600770035","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600770035?lang=zh_cn&edition=full","pubTime":"2026-01-02 02:15","pubTimestamp":1767291312,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，康恩贝报收于4.51元，较上周的4.66元下跌3.22%。本周关注点公司公告汇总：子公司盐酸丙卡特罗吸入溶液获药品注册证书，视同通过仿制药一致性评价。截至目前，金华康恩贝对该产品累计研发投入约685万元。徐春玲女士持有公司股份50,000股，不存在未履行完毕的公开承诺，将继续遵守相关减持规定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000519.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0028","600572","BK0012","BK0097","BK0060"],"gpt_icon":0},{"id":"2595935617","title":"康恩贝最新公告：选举应徐颉任董事长","url":"https://stock-news.laohu8.com/highlight/detail?id=2595935617","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595935617?lang=zh_cn&edition=full","pubTime":"2025-12-30 17:32","pubTimestamp":1767087172,"startTime":"0","endTime":"0","summary":"康恩贝(600572.SH)公告称，12月30日，公司召开第十一届董事会第十四次（临时）会议，审议通过《关于选举公司董事长、副董事长的议案》《关于选举代表公司执行公司事务董事的议案》等议案。全体董事一致同意选举应徐颉任公司第十一届董事会董事长、金军丽任公司第十一届董事会副董事长；同意选举应徐颉为代表公司执行公司事务的董事，并担任公司法定代表人。以上人员任期均自本次董事会审议通过之日起至第十一届董事会任期届满之日止。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000029145.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0060","600572","BK0097","BK0239","BK0012","BK0028"],"gpt_icon":0},{"id":"2594424522","title":"每周股票复盘：康恩贝（600572）股东会增补两名董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2594424522","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594424522?lang=zh_cn&edition=full","pubTime":"2025-12-28 04:09","pubTimestamp":1766866150,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，康恩贝报收于4.51元，较上周的4.66元下跌3.22%。股本股东变化：第二大股东康恩贝集团拟通过大宗交易减持不超过2%股份，控股股东浙药集团将受让该股份。公司公告汇总浙江康恩贝制药股份有限公司于2025年12月22日召开2025年第二次临时股东会，审议通过增补应徐颉、金军丽为公司第十一届董事会非独立董事的议案。本次减持的受让方为公司控股股东浙江省医药健康产业集团有限公司，减持不会导致公司控制权变更。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800001010.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0012","BK0097","BK0028","BK0239","BK0188","600572"],"gpt_icon":0},{"id":"2593482905","title":"A股公告精选 | 康恩贝(600572.SH)拟转让2%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2593482905","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593482905?lang=zh_cn&edition=full","pubTime":"2025-12-22 19:59","pubTimestamp":1766404770,"startTime":"0","endTime":"0","summary":"康恩贝：第二大股东康恩贝集团以大宗交易方式向控股股东转让2%公司股份","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20251222/20251222200019_89638.png?x-oss-process=image/format,jpg/quality,q_60&image_source=0","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251222/20251222200019_89638.png?x-oss-process=image/format,jpg/quality,q_60&image_source=0"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["600572","159982","BK0239","BK0097","BK0028","399300","BK0012","BK0188","BK0060"],"gpt_icon":0},{"id":"1108162412","title":"康恩贝公告股东计划于1月16日至4月15日之间减持最多2%的股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1108162412","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108162412?lang=zh_cn&edition=full","pubTime":"2025-12-22 18:37","pubTimestamp":1766399853,"startTime":"0","endTime":"0","summary":"康恩贝公告股东计划于1月16日至4月15日之间减持最多2%的股份","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","BK0188","BK0097","BK0239","BK0028","BK0012","600572"],"gpt_icon":0},{"id":"2593486285","title":"康恩贝(600572.SH)控股股东拟增持1.999%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2593486285","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593486285?lang=zh_cn&edition=full","pubTime":"2025-12-22 18:21","pubTimestamp":1766398869,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康恩贝(600572.SH)发布公告，基于对公司发展前景的坚定信心、对公司长期投资价值的认可，以及进一步提升控制力的需要，公司控股股东浙药集团计划于自公告披露之日后15个交易日后的3个月内通过上海证券交易所以大宗交易的方式增持公司股份，拟增持股数为5065.9万股，占公司现总股本的1.999%。公司第二大股东康恩贝集团有限公司(简称“康恩贝集团”)为本次浙药集团增持股份的大宗交易转让方。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384491.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康恩贝(600572.SH)控股股东拟增持1.999%公司股份","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600572","BK0028","BK0188","BK0060","BK0012","BK0097","BK0239"],"gpt_icon":0},{"id":"2590263579","title":"康恩贝董事长“闪离”背后：频繁人事震荡与增长乏力下的治理隐忧","url":"https://stock-news.laohu8.com/highlight/detail?id=2590263579","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590263579?lang=zh_cn&edition=full","pubTime":"2025-12-12 16:24","pubTimestamp":1765527840,"startTime":"0","endTime":"0","summary":"12月5日，浙江康恩贝制药股份有限公司一纸公告，宣布董事长、法定代表人姜毅因“工作调整”辞去所有职务，其董事会任期原应至2027年。自2024年8月正式掌舵至离任，其任职时间不足一年半。一同辞任的还有一位董事。在业绩承压、股价长期低迷的背景下，这一高频人事变动迅速引发市场对其内部治理与战略连续性的深切担忧。康恩贝当前的回应，显然未能有效安抚市场。 人事震荡之外，康恩贝的基本面同样凸显隐忧。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2025-12-12/doc-inhaprxi5673564.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0188","BK0060","BK0097","600572","BK0028","BK0239","BK0012"],"gpt_icon":0},{"id":"2586733559","title":"康恩贝（600572）披露关于减少注册资本通知债权人的公告，11月28日股价下跌0.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586733559","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586733559?lang=zh_cn&edition=full","pubTime":"2025-11-28 22:27","pubTimestamp":1764340039,"startTime":"0","endTime":"0","summary":"截至2025年11月28日收盘，康恩贝报收于4.62元，较前一交易日下跌0.65%，最新总市值为116.73亿元。公司近日发布公告称，浙江康恩贝制药股份有限公司因注销回购股份，注册资本将由2,570,037,319元减少至2,506,458,271元，总股本减少63,579,048股。公司已于2025年10月27日召开董事会会议，于2025年11月13日召开临时股东大会，审议通过相关议案。申报方式包括现场递交或邮寄，申报期间为2025年11月29日至2026年1月12日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800040500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0239","600572","BK0097","BK0012","BK0060"],"gpt_icon":0},{"id":"2585549854","title":"康恩贝（600572）披露2022年股票期权激励计划首次授予股票期权第二个行权期自主行权实施公告，11月24日股价上涨0.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585549854","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585549854?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:26","pubTimestamp":1763994384,"startTime":"0","endTime":"0","summary":"截至2025年11月24日收盘，康恩贝报收于4.58元，较前一交易日上涨0.44%，最新总市值为115.72亿元。该股当日开盘4.59元，最高4.64元，最低4.57元，成交额达1.57亿元，换手率为1.36%。近日，浙江康恩贝制药股份有限公司发布关于2022年股票期权激励计划首次授予股票期权第二个行权期自主行权实施的公告。行权起始日为2025年11月28日，行权期限为2025年11月28日至2026年11月27日间的交易日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400035883.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0060","600572","BK0097","BK0239","BK0012","BK0028"],"gpt_icon":0},{"id":"2585345255","title":"浙金信托接手大连万达商管旗下两家公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2585345255","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585345255?lang=zh_cn&edition=full","pubTime":"2025-11-24 16:34","pubTimestamp":1763973240,"startTime":"0","endTime":"0","summary":"11月24日，据天眼查披露的信息显示，11月21日，大连万颛企业管理有限公司发生工商变更，原股东大连万达商业管理集团股份有限公司退出，新增苏州联商柒号商业管理有限公司为全资股东，同时法定代表人、主要人员均有所变更。 另外，苏州联商柒号商业管理有限公司还接手了大连万达商业管理集团股份有限公司旗下的大连统南企业管理有限责任公司。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2025-11-24/doc-infynvux5750729.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-11-24/doc-infynvux5750729.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","BK0188","600572","600120","BK0143","BK0097","BK0239","LU1781817850.SGD","BK0276","BK0118","BK0009","LU1508157978.USD","BK0272","601995","BK0052","LU2663582299.SGD","BK0060","BK0012","000411","BK0074","BK0250","BK0102","LU1580142542.USD"],"gpt_icon":0},{"id":"2583651153","title":"每周股票复盘：康恩贝（600572）集团减持1%股份至12.792%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583651153","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583651153?lang=zh_cn&edition=full","pubTime":"2025-11-16 03:40","pubTimestamp":1763235628,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，康恩贝报收于4.83元，较上周的4.76元上涨1.47%。本周，康恩贝11月14日盘中最高价报4.87元。本周关注点股本股东变化：康恩贝集团减持1.000%股份，持股比例降至12.792%。减持完成后，康恩贝集团及一致行动人胡季强合计持股比例为12.792%。关于2022年股票期权激励计划部分股票期权注销完成的公告因激励对象退休、离职或绩效考核未达标，康恩贝于2025年11月6日决定注销202.92万份已获授但未行权的股票期权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000927.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0060","600572","BK0188","BK0028","BK0097","BK0239"],"gpt_icon":0},{"id":"2582368928","title":"11月11日康恩贝发布公告，股东减持470.26万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2582368928","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582368928?lang=zh_cn&edition=full","pubTime":"2025-11-11 19:01","pubTimestamp":1762858882,"startTime":"0","endTime":"0","summary":"证券之星消息，11月11日康恩贝发布公告《康恩贝:股东减持股份结果公告》，其股东康恩贝集团有限公司于2025年11月7日至2025年11月11日间合计减持470.26万股，占公司目前总股本的0.1861%，变动期间该股股价上涨0.84%，截止11月11日收盘报4.8元。股东增减持详情见下表：根据康恩贝2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100032914.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0097","BK0060","BK0239","BK0012","600572"],"gpt_icon":0},{"id":"2582866724","title":"每周股票复盘：康恩贝（600572）股东减持2376.16万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2582866724","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582866724?lang=zh_cn&edition=full","pubTime":"2025-11-09 02:18","pubTimestamp":1762625894,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，康恩贝报收于4.76元，较上周的4.68元上涨1.71%。本周关注点股本股东变化：股东胡季强、康恩贝集团有限公司合计减持2376.16万股，占总股本0.9411%。期间股价上涨6.73%，截至11月6日收盘报4.76元。康恩贝集团及其一致行动人胡季强持股比例由13.944%降至12.992%，权益变动触及1%刻度。胡季强减持3,221,600股，康恩贝集团减持20,540,000股，均通过集中竞价交易完成。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900000426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600572","BK0012","BK0188","BK0028","BK0060","BK0097","BK0239"],"gpt_icon":0},{"id":"2581417068","title":"11月6日康恩贝发布公告，股东减持2376.16万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2581417068","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581417068?lang=zh_cn&edition=full","pubTime":"2025-11-06 18:01","pubTimestamp":1762423289,"startTime":"0","endTime":"0","summary":"证券之星消息，11月6日康恩贝发布公告《康恩贝:关于持股5%以上股东权益变动触及1%刻度的提示性公告》，其股东胡季强、康恩贝集团有限公司于2025年9月4日至2025年11月6日间合计减持2376.16万股，占公司目前总股本的0.9411%，变动期间该股股价上涨6.73%，截止11月6日收盘报4.76元。股东增减持详情见下表：根据康恩贝2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600028557.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0097","BK0028","600572","BK0188","BK0239","BK0060"],"gpt_icon":0},{"id":"2580475351","title":"每周股票复盘：康恩贝（600572）Q3净利增69.11%，股东户数降3.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580475351","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580475351?lang=zh_cn&edition=full","pubTime":"2025-11-02 02:43","pubTimestamp":1762022590,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，康恩贝报收于4.68元，较上周的4.47元上涨4.7%。本周，康恩贝10月31日盘中最高价报4.7元。股本股东变化截至2025年9月30日，康恩贝股东户数为8.67万户，较6月30日减少3128.0户，减幅3.48%。业绩披露要点康恩贝2025年三季报显示，主营收入49.76亿元，同比上升1.27%；归母净利润5.84亿元，同比上升12.65%；扣非净利润4.31亿元，同比上升1.61%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200000445.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0012","BK0028","BK0188","600572","BK0097","BK0239"],"gpt_icon":0},{"id":"2578350249","title":"康恩贝(600572)9月30日股东户数8.67万户，较上期减少3.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578350249","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578350249?lang=zh_cn&edition=full","pubTime":"2025-10-28 17:17","pubTimestamp":1761643057,"startTime":"0","endTime":"0","summary":"证券之星消息，近日康恩贝披露，截至2025年9月30日公司股东户数为8.67万户，较6月30日减少3128.0户，减幅为3.48%。在中药行业个股中，康恩贝股东户数高于行业平均水平，截至9月30日，中药行业平均股东户数为5.36万户。从股价来看，2025年6月30日至2025年9月30日，康恩贝区间跌幅为0.68%，在此期间股东户数减少3128.0户，减幅为3.48%。根据统计，康恩贝2025年6月30日至2025年9月30日，主力资金净流出2.68亿元，游资资金净流入6198.78万元，散户资金净流入2.06亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800030738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0012","BK0239","BK0060","BK0097","600572","BK0028"],"gpt_icon":0},{"id":"2578935422","title":"康恩贝最新公告：第三季度净利润为2.3亿元同比增长69.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578935422","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578935422?lang=zh_cn&edition=full","pubTime":"2025-10-28 17:14","pubTimestamp":1761642844,"startTime":"0","endTime":"0","summary":"康恩贝(600572.SH)发布2025年第三季度报告，第三季度营收为16.17亿元，同比增长10.42%；净利润为2.3亿元，同比增长69.11%。前三季度净利润为5.84亿元，同比增长12.65%。本期净利润增长主要系本报告期末公司主营业务业绩增长、所持嘉和生物股份期末市值较上年同期市值增加。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800030367.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600572"],"gpt_icon":0},{"id":"2578356969","title":"康恩贝最新公告：腺苷钴胺胶囊拟中标第十一批全国药品集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2578356969","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578356969?lang=zh_cn&edition=full","pubTime":"2025-10-28 17:07","pubTimestamp":1761642442,"startTime":"0","endTime":"0","summary":"康恩贝(600572.SH)公告称，公司全资子公司杭州康恩贝参加了国家组织第十一批药品集中带量采购工作，产品腺苷钴胺胶囊拟中标本次集中采购。中选结果将在联合采购办公室公示后正式发布。腺苷钴胺胶囊适用于巨幼红细胞性贫血等症状，是《国家基本医疗保险、工伤保险和生育保险药品目录（2024年版）》甲类药品。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800029982.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0012","BK0239","600572","BK0188","BK0097","BK0060"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768262497836,"stockEarnings":[{"period":"1week","weight":0.0089},{"period":"1month","weight":-0.0152},{"period":"3month","weight":0.0249},{"period":"6month","weight":-0.0088},{"period":"1year","weight":0.074},{"period":"ytd","weight":0.0157}],"compareEarnings":[{"period":"1week","weight":0.0353},{"period":"1month","weight":0.0709},{"period":"3month","weight":0.0776},{"period":"6month","weight":0.1888},{"period":"1year","weight":0.3146},{"period":"ytd","weight":0.0495}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江康恩贝制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"79985人(较上一季度增加0.40%)","perCapita":"31603股","listingDate":"2004-04-12","address":"浙江省金华市兰溪市康恩贝大道1号","registeredCapital":"253456万元","survey":" 浙江康恩贝制药股份有限公司的主营业务是药品、中药饮片及大健康产品的研发、制造及销售。公司的主要产品是中成药、中药材与中药饮片、中药保健品及中药提取物、中药OTC及中药处方药业务。","listedPrice":8.25},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康恩贝(600572)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康恩贝(600572)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康恩贝,600572,康恩贝股票,康恩贝股票老虎,康恩贝股票老虎国际,康恩贝行情,康恩贝股票行情,康恩贝股价,康恩贝股市,康恩贝股票价格,康恩贝股票交易,康恩贝股票购买,康恩贝股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康恩贝(600572)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康恩贝(600572)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}